Hasan Jafri - May 4, 2023 Form 4 Insider Report for Aridis Pharmaceuticals, Inc. (ARDS)

Role: Chief Medical Officer
Signature: /s/ Hasan Jafri
Stock symbol: ARDS
Transactions as of: May 4, 2023
Transactions value $: $0
Form type: 4
Date filed: 6/15/2023, 05:11 PM
Previous filing: Dec 7, 2022
Next filing: Sep 19, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ARDS	Common Stock	Options Exercise		+10K	+196.08%		15.1K	Jun 5, 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ARDS	Stock Options	Award	$0	+25K	+19.23%	$0.00	155K	May 4, 2023	Common Stock	25K	$0.16	Direct	F1
transaction	ARDS	Restricted Stock Units	Options Exercise		-10K	-50%		10K	Jun 5, 2023	Common Stock	10K		Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	50% of the options vest on the three month anniversary of the date of grant and the remainder vest on the six month anniversary of the date of grant.
F2	Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F3	10,000 shares of Common Stock vested on June 5, 2023 and 10,000 will vest on 12/5/2023. In the event that the Reporting Person's employment is terminated without cause by the Issuer, the RSUs will immediately vest.